Metabolic effects of oral versus transdermal 17β-estradiol (E 2): A randomized clinical trial in girls with turner syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 7, 2013, Pages 2716-2724

  Torres Santiago, L ^a,b   Mericq, V ^c   Taboada, M ^a,d   Unanue, N ^j   Klein, K O ^e   Singh, R ^f   Hossain, J ^g   Santen, R J ^h   Ross, J L ⁱ   Mauras, Nelly ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF CHILE   (Chile)

^d NEMOURS CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MAYO CLINIC   (United States)

^g NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^h UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; GLUCOSE; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OSTEOCALCIN; SEX HORMONE BINDING PROTEIN; SOMATOMEDIN C;

ADOLESCENT; ADULT; ARTICLE; BIOASSAY; BODY COMPOSITION; BONE DENSITY; CALORIMETRY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; ESTRONE BLOOD LEVEL; FAT FREE MASS; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HUMAN; HYPOGONADISM; KARYOTYPE 45,X; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MENSTRUATION; METABOLITE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUBERTY; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TURNER SYNDROME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BASAL METABOLISM; BIOTRANSFORMATION; BODY COMPOSITION; BONE DENSITY; DRUG MONITORING; ENERGY METABOLISM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTRONE; FEASIBILITY STUDIES; FEMALE; HUMANS; LIPID METABOLISM; TRANSDERMAL PATCH; TURNER SYNDROME; YOUNG ADULT;

EID: 84879918331     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4243     Document Type: Article

References (35)

1. O'Sullivan AJ, Crampton LJ, Freund J, Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest. 1998;102:1035-1040. (Pubitemid 28419248)
2. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25:693-721. (Pubitemid 39366048)
3. Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab. 1999;84:3956-3960. (Pubitemid 30644180)
4. Hänggi W, Lippuner K, Jaeger P, Birkhäuser MH, Horber FF. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clin Endocrinol (Oxf). 1998;48:691-699. (Pubitemid 28289236)
5. Gravholt CH, Hjerrild BE, Naeraa RW, Engbaek F, Mosekilde L, Christiansen JS. Effect of growth hormone and 17β-oestradiol treatment on metabolism and body composition in girls with Turner syndrome. Clin Endocrinol (Oxf). 2005;62:616-622. (Pubitemid 40646732)
6. Drobac S, Rubin K, Rogol AD, Rosenfield RL. A workshop on pubertal hormone replacement options in the United States. J Pediatr Endocrinol Metab. 2006;19:55-64. (Pubitemid 43257421)
7. Taboada M, Santen R, Lima J, Hossain J, Singh R, Klein KO, Mauras N. Pharmacokinetics and pharmacodynamics of oral and transdermal 17β estradiol in girls with Turner syndrome. J Clin Endocrinol Metab. 2011;96:3502-3510.
8. Nelson RE, Grebe SK, OKane DJ, Singh RJ. Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem. 2004;50:373-384. (Pubitemid 38156379)
9. Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev. 2007;16:1713-1719. (Pubitemid 47450498)
10. Santen RJ, Demers L, Ohorodnik S, et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids. 2007;72:666-671. (Pubitemid 46977432)
11. Santen RJ, Lee JS, Wang S, et al. Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. Steroids. 2008;73:1318-1321.
12. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest. 1994;94:2475-2480. (Pubitemid 24379624)
13. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metab Clin Exp. 1988;37:287-301. (Pubitemid 18080935)
14. Södergård R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17B to human plasma proteins at body temperature. J Steroid Biochem. 1982;16:801-810. (Pubitemid 13228095)
15. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672. (Pubitemid 30645223)
16. Nabhan ZM, Dimeglio LA, Qi R, Perkins SM, Eugster EA. Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. J Clin Endocrinol Metab. 2009;94:2009-2014.
17. Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta. 2004;1654:123-143. (Pubitemid 38681205)
18. Klein KO, Baron J, Barnes KM, Pescovitz OH, Cutler GB Jr. Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist. J Clin Endocrinol Metab. 1998;83:2387-2389. (Pubitemid 28503034)
19. Klein KO, Demers LM, Santner SJ, Baron J, Cutler GB Jr, Santen RJ. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab. 1995;80:2658-2660.
20. Klein KO, Mericq V, Brown-Dawson JM, Larmore KA, Cabezas P, Cortinez A. Estrogen levels in girls with premature thelarche compared with normal prepubertal girls as determined by an ultrasensitive recombinant cell bioassay. J Pediatr. 1999;134:190-192. (Pubitemid 29089043)
21. Masamura S, Santner SJ, Santen RJ. Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase. J Steroid Biochem Mol Biol. 1996;58:425-429. (Pubitemid 26348977)
22. Mauras N, Rogol AD, Veldhuis JD. Estrogenic modulation of the gonadotropin-releasing hormone-stimulated secretory activity of the gonadotrope and lactotrope in prepubertal females with Turner's syndrome. J Clin Endocrinol Metab. 1991;73:1202-1209. (Pubitemid 121000693)
23. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991;72:374-381. (Pubitemid 21921702)
24. Leong GM, Moverare S, Brce J, et al. Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology. 2004;145:5525-5531.
25. dos Reis CM, de Melo NR, Meirelles ES, Vezozzo DP, Halpern A. Body composition, visceral fat distribution and fat oxidation in postmenopausal women using oral or transdermal oestrogen. Maturitas. 2003;46:59-68.
26. Mauras N, Shulman D, Hsiang HY, Balagopal P, Welch S. Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with turner syndrome. J Clin Endocrinol Metab. 2007;92:4154-4160. (Pubitemid 350074725)
27. Jospe N, Orlowski CC, Furlanetto RW. Comparison of transdermal and oral estrogen therapy in girls with Turner's syndrome. J Pediatr Endocrinol Metab. 1995;8:111-116.
28. Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study. J Clin Endocrinol Metab. 2002;87:2798-2808. (Pubitemid 34655347)
29. Sweetland S, Beral V, Balkwill A, et al; The Million Women Study C. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10:2277-2286.
30. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336:1227-1231. (Pubitemid 351809317)
31. Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519-c2519.
32. Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA; United Kingdom Clinical Cytogenetics Group. Mortality in women with Turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab. 2008;93:4735-4742.
33. Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab. 2006;91:3897-3902. (Pubitemid 44536861)
34. Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol. 1998;51:147-158. (Pubitemid 28066141)
35. Mauras N, Delgiorno C, Kollman C, et al. Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab. 2010;95:1060-1068. Activities